As teriflunomide specially blocks the proliferation of auto-reactive lymphocytes and not other lymphocytes bearing TCR specific to foreign antigens (such as SARS-CoV-2 S protein), MS patients under therapy with teriflunomide will confer protective immune responses against the COVID-19 vaccines [49,95]. This evidence concerns the gene PROS1 and COVID-19.